Proteios Technology, Inc.
Issaquah, WA
- UEI
- G6QLLQD9UMT1
- CAGE
- 7FC04
- Primary NAICS
- 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
- SAM.gov registration
- Active through
Company facts
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- Other NAICS codes in SAM.gov
- SAM.gov registration date
- Physical address
- 580 Wilderness Peak Dr NW, Issaquah, WA 98027, USA
- Website
- proteios.com
- Founded
- 2015
- Employees
- 1-10
- Estimated annual revenue
- $0-$1M
- Industry
-
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- Biotechnology
- SIC code
- 28 Chemical & Allied Products
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Contract obligations by fiscal year
| Fiscal year | Obligated |
|---|---|
| FY2027 To date | $0 |
| FY2026 | $0 |
| FY2025 | $0 |
| FY2024 | $0 |
| FY2023 | $2,049,979 |
Contract awards
Grant awards
Similar vendors
About the company
Proteios Technology, Inc. is a biotech company specializing in sustainable protein purification using eco-friendly silica technology for the biopharmaceutical production and cell therapy sectors. As a self-certified small disadvantaged business, this for-profit corporation provides research, development, and manufacturing services to federal agencies primarily through the National Institutes of Health and the National Science Foundation.
Through prime federal contracts, Proteios Technology conducts research and development to support innovative solutions for autologous and allogeneic cell therapy manufacturing. This includes a $2 million Small Business Innovation Research Phase II contract with the National Cancer Institute to develop a new paradigm for cell therapy manufacturing over a two-year period. Additionally, Proteios was awarded a $455,000 Small Business Innovation Research Phase I contract by the National Cancer Institute to perform one year of research and development activities focused on cell therapy manufacturing processes. Both contracts were set aside for total small business participation.
Through federal grants, Proteios develops cell separation tools and manufacturing instruments to reduce the cost of cell therapies. This includes a $2.4 million National Institute of General Medical Sciences project grant to create cell separation cartridges for cluster of differentiation marker proteins, providing researchers and manufacturers with a tag-free, antibody-free cell isolation platform. Proteios also received a $949,999 National Science Foundation grant supporting the removal of purification bottlenecks in biopharmaceutical production over a 2.5-year period.
SBA capabilities narrative
Proteios incorporates proprietary protein technology into protein purification kits to allow Life Science researchers to quickly and easily purify proteins manufactured through recombinant technology. A short polypeptide is attached to the recombinant protein, which allows the protein to be captured on silica gel.
Quick answers
Is Proteios Technology, Inc. registered in SAM.gov?
Yes. Proteios Technology, Inc.'s SAM.gov registration is active through March 22, 2027.
What is Proteios Technology, Inc.'s CAGE code?
Proteios Technology, Inc.'s CAGE code is 7FC04, and its Unique Entity ID (UEI) is G6QLLQD9UMT1.
How much has Proteios Technology, Inc. received in federal contracts?
Federal contracts obligated $2,049,979 to Proteios Technology, Inc. in fiscal years 2023 through 2027.
What is Proteios Technology, Inc.'s most recent federal award?
Proteios Technology, Inc.'s most recent federal contract award is Sbir phase II, topic 429: a new paradigm for autologous and allogeneic cell therapy manufacturing (75N91023C00028), from National Cancer Institute (NIH), on September 15, 2023.
On GovTribe
See Proteios Technology, Inc.'s full federal record
- Federal contract awards
- Federal grant awards
- Funding analysis by agency, NAICS and set-aside
- Similar vendors